Julie Stein Perry

No ORCID on file · 5 papers in corpus · active 2022-2024

Study types

  • article 5

Condition tags

  • endometriosis 5
  • dysmenorrhea 2
  • chronic_pelvic_pain 1
  • dyspareunia 1
article 2024
Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study
Human Reproduction ·doi:10.1093/humrep/dead263

STUDY QUESTION: What is the efficacy and safety of long-term treatment (up to 2 years) with relugolix combination therapy (CT) in women with moderate to severe endometriosis-associated pain? SUMMARY ANSWER: For up to 2 years, treatment with…

article 2022
EVALUATION OF THE EFFECT OF RELUGOLIX COMBINATION THERAPY ON BONE MINERAL DENSITY (BMD) OVER TWO YEARS IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN: SPIRIT LONG-TERM EXTENSION (LTE) STUDY
·doi:10.1016/j.fertnstert.2022.08.631
article 2022
O-305 SPIRIT long-term extension study: two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain
·doi:10.1093/humrep/deac105.102

Abstract Study question To assess the long-term efficacy and safety of once-daily Relugolix combination therapy (Relugolix-CT) in the treatment of endometriosis-associated pain over two years. Summary answer Relugolix-CT previously demonstr…

article 2022
RELUGOLIX COMBINATION THERAPY IN NORTH AMERICAN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN: SPIRIT 1 AND 2 TRIALS
·doi:10.1016/j.fertnstert.2022.08.633
article 2022
TIME TO MINIMAL OR NO PELVIC PAIN WITH RELUGOLIX COMBINATION THERAPY IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN: RESULTS FROM THE SPIRIT PROGRAM
·doi:10.1016/j.fertnstert.2022.08.035